Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC11 | Q96DB2 | 12/20 | 0.83 |
| ▸ | DRD2 | P14416 | 1/20 | 0.47 |
| ▸ | HTR2A | P28223 | 1/20 | 0.47 |
| ▸ | HTR2C | P28335 | 1/20 | 0.47 |
| ▸ | HTR2B | P41595 | 1/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.47 |
| ▸ | FABP4 | P15090 | 2/20 | 0.46 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.44 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
| ▸ | PARP1 | P09874 | 1/20 | 0.39 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20096690 | 1.00 | HDAC11 (0.83) | HDAC11DRD2HTR2AHTR2CHTR2B | |
| SCHEMBL20132912 | 0.91 | HDAC11 (1.00) | HDAC11DRD2HTR2AHTR2CHTR2B | |
| SCHEMBL20096701 | 0.90 | HDAC11 (0.79) | HDAC11DRD2HTR2AHTR2CHTR2B | |
| SCHEMBL20096618 | 0.84 | HDAC11 (0.88) | HDAC11DRD2HTR2AHTR2CHTR2B | |
| SCHEMBL20096857 | 0.83 | HDAC11 (0.86) | HDAC11PTGER4HCRTR2HDAC6 | |
| SCHEMBL20096845 | 0.81 | HDAC11 (0.66) | HDAC11PTGER4HDAC6 | |
| SCHEMBL20096692 | 0.79 | HDAC11 (0.79) | HDAC11HDAC6 | |
| SCHEMBL20096696 | 0.78 | HDAC11 (0.80) | HDAC11PTGER4HDAC6 | |
| SCHEMBL20132806 | 0.78 | HDAC11 (0.62) | HDAC11HDAC6 | |
| SCHEMBL20096709 | 0.78 | HDAC11 (0.77) | HDAC11PTGER4HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220235018-A1 | METHODS USING HDAC11 INHIBITORS | Valo Health, LLC | 2022-07-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220235018-A1 | METHODS USING HDAC11 INHIBITORS | HDAC11, HDAC1, HDAC10 | HDAC11 1/4885DRD2 4805/4885HTR2A 4424/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.